Vida Pharmacal

What Vida Pharmacal does

Vida Pharmacal is a privately held, founder-led pharmaceutical company headquartered in Spring Branch, Texas, that develops, markets, and distributes diagnostics and therapeutics targeting Chagas disease (Trypanosoma cruzi infection) in veterinary and human patients. Founded in 2017 by veterinarian Dr. Roy Madigan, the company operates two divisions, Vida Animal Health and Vida Human Health, and was the first company devoted to developing a treatment for Chagas disease in veterinary patients. Headcount is small at 1-10 employees and no institutional investors or funding rounds are disclosed.

The product platform centers on Vidarone (also branded Amiozole or V1001), a proprietary, patented combination of amiodarone and itraconazole that demonstrated over 95% T. cruzi parasite clearance in Stanford University studies using stem-cell-derived live human cardiac cells, versus under 60% for benznidazole. The company has also developed a novel high-accuracy lateral flow diagnostic assay for point-of-care Chagas screening in both canine and human patients, and in June 2026 received FDA Priority Zoonotic Animal Drug (PZAD) designation — the first such designation for Chagas. Clinical and research data have been published in JAVMA, Parasites & Vectors, and PLOS Neglected Tropical Diseases, with the JAVMA multicenter field study establishing the first reported cure for canine Chagas disease.

Commercially, Vida Pharmacal sells through veterinary healthcare providers (cardiologists, specialty clinics, and general practitioners) using a quote-based B2B enterprise field sales motion, with pricing not publicly disclosed. The company has also demonstrated cross-species efficacy through an engagement with SeaWorld for treatment of a Chagas-positive walrus. Distribution is currently regional (Southern United States) and revenue is not disclosed, with the core therapeutic still described as pending full FDA approval for canine use. Forward positioning emphasizes expansion into human diagnostics via a Rockefeller Foundation-supported study and a broader alliance network including DNDI, CDC, and academic partners.

Name

Vida Pharmacal

Legal name

Vida Pharmacal

Website

https://vidapharmacal.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Vida Pharmacal is a privately held pharmaceutical company that develops, markets, and distributes diagnostics and therapeutics for Chagas disease in veterinary and human patients, with its Vidarone combination therapy and lateral flow assay being the first products targeting canine Chagas disease. It sells through veterinary clinics and is expanding into human point-of-care diagnostics.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)

akta.pro secondary industry

Compounding Pharmacies (Veterinary) (HLAMAIAD)

Keywords

• Chagas disease treatment
• Veterinary pharmaceuticals
• Diagnostic assay development
• Neglected tropical diseases
• Zoonotic disease therapeutics

Headquarters

HQ city

Spring Branch

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Sales: Revenue from sale of proprietary Chagas disease treatment (Vidarone/V1001) to veterinarians and animal health providers for treatment of canine Chagas disease.
2. Diagnostic Products: Revenue from lateral flow diagnostic assays for Chagas disease screening in veterinary and human patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Vida Pharmacal develops, manufactures, and distributes a proprietary pharmaceutical treatment (Vidarone / V1001, an amiodarone + itraconazole combination) and a novel lateral flow diagnostic assay for Chagas disease (Trypanosoma cruzi infection). Products are sold primarily to veterinarians and veterinary clinics for canine Chagas diagnosis and treatment, with emerging human applications through the Vida Human Health division.

Product overview

Vida Pharmacal develops, markets, and distributes diagnostics and pharmaceuticals designed to treat Chagas disease in both veterinary and human patients. The company operates two divisions: Vida Animal Health and Vida Human Health. Its core product portfolio consists of Vidarone (a proprietary amiodarone + itraconazole therapeutic), the V1001 treatment product, and a novel lateral flow diagnostic assay. The company has developed the world's first treatment for Chagas disease in canines and is working toward approval for human treatment. The therapeutic pipeline includes Vidarone, which demonstrated over 95% efficacy in clearing the T. cruzi parasite during Stanford University studies using human cardiac stem cells.

Differentiator

Problem solved

Functional benefit

Brands

• Vida Animal Health: Product line focused on canine Chagas disease diagnosis and treatment
• Vida Human Health
• Vidarone
• V1001

Products and services

• Vidarone (V1001) - Amiodarone + Itraconazole Combination Therapy Proprietary, patented therapeutic drug combining amiodarone and itraconazole for treating Chagas disease (Trypanosoma cruzi infection) in canine patients. First-to-market treatment for canine Chagas disease and pending approval for human use. Demonstrated over 95% parasite clearance in Stanford University human cardiac cell studies versus less than 60% for benznidazole.
• Lateral Flow Diagnostic Assay for Chagas Disease Novel high-accuracy lateral flow diagnostic test enabling in-clinic screening and early identification of Chagas disease in canine and human patients. First high-accuracy point-of-care lateral flow assay used for human Chagas disease screening.
• Vida Animal Health Treatment Line (V1001) Treatment product for canine Chagas disease sold under the Vida Animal Health product line, providing veterinarians the first commercially available therapeutic option for dogs infected with T. cruzi.

Quantifiable outcome

• Over 95% parasite clearance rate in Stanford University studies using human cardiac stem cells
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Stanford UniversitycoreStrategic or Co-development Partner · 1 January 2017Rigorous research study conducted at Stanford University using innovative approach to grow live, beating human heart cells in vitro. The study introduced Chagas disease into healthy human cardiac cells and treated with Vida Pharmacal's medication and Benznidazole, demonstrating >95% parasite clearance vs <60% for Benznidazole alone.
• Dr. Alberto E. Paniz MondolficoreStrategic or Co-development PartnerPhysician in Venezuela who first documented successful treatment of human Chagas patient using amiodarone and itraconazole combination therapy. Collaborated with Dr. Madigan to develop treatment protocol for canine Chagas disease and provided laboratory testing for T. cruzi samples from U.S. dogs.
• Texas A&M UniversityminorStrategic or Co-development PartnerVeterinary school that received tissue samples from initial Chagas case (Max) and performed testing that confirmed Trypanosoma cruzi parasite in cardiac tissue, establishing the first U.S. canine Chagas diagnosis.
• Lackland Air Force BaseminorStrategic or Co-development PartnerU.S. Air Force base where Vida Pharmacal conducted long-term study of Chagas disease in military working dogs, generating clinical data on treatment efficacy.
• SeaWorldminorStrategic or Co-development PartnerWildlife park that engaged Vida Pharmacal for treatment of a Chagas-positive walrus, representing the first documented case of Chagas disease in a walrus. Required dosing adaptation for 1,000-pound animal.
• DNDI (Drugs for Neglected Diseases initiative)minorStrategic or Co-development PartnerNon-profit partnership supporting development of treatments for neglected tropical diseases including Chagas disease.
• Chagas Task Force of TexasminorStrategic or Co-development PartnerCollaborative organization focused on Chagas disease awareness, testing, and treatment in Texas. Linked as partner organization on Vida Pharmacal website.
• CDC (Centers for Disease Control and Prevention)minorStrategic or Co-development PartnerCDC referenced as partner organization providing educational resources on Chagas disease prevention and treatment.
• Rockefeller StudycoreStrategic or Co-development PartnerStarting June 1, 2026, Vida Pharmacal's novel lateral flow assay is being used for the first time to diagnose acute or chronic Chagas disease in humans in a Rockefeller Foundation-supported study, marking first human point-of-care screening deployment.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/vidapharmacal
• YouTubeyoutube.com/@chasingchagas
• Facebookfacebook.com/chagascure
• LinkedInlinkedin.com/company/vida-pharmacal
• Instagraminstagram.com/vidapharmacal

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vida Pharmacal